{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:29:53Z","timestamp":1748302193557,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We evaluated the incidence of febrile neutropenia (FN) and related clinical outcomes among patients treated with myelosuppressive chemotherapy for nonmyeloid malignancies who received pegfilgrastim on-body injector (OBI) or other options (Other) for FN prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective observational study, adult patients with breast, prostate, or lung cancer, or non-Hodgkin lymphoma at risk for FN were stratified into subgroups based on FN prophylaxis used in the first chemotherapy cycle: pegfilgrastim OBI vs Other (pegfilgrastim or biosimilar pegfilgrastim prefilled syringe, daily filgrastim, or no granulocyte colony\u2013stimulating factor [G-CSF]) for up to 4 planned chemotherapy cycles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This US study enrolled 2575 eligible patients (OBI, 1624; Other, 951). FN incidence was lower in the OBI group (6.4% [95% CI, 5.2\u20137.6%]) than in the Other group (9.4% [7.5\u201311.2%]), with a relative risk (RR) of 0.66 (0.47\u20130.91; <jats:italic>p<\/jats:italic>\u2009=\u2009.006). A decreased risk of dose delays among patients receiving pegfilgrastim OBI vs Other was observed (RR for\u2009\u2265\u20095\u00a0days: 0.64 [0.42\u20130.96], <jats:italic>p<\/jats:italic>\u2009=\u2009.023; RR for\u2009\u2265\u20097\u00a0days: 0.62 [0.40\u20130.91], <jats:italic>p<\/jats:italic>\u2009=\u2009.016). Adherence, defined as G-CSF support for all chemotherapy cycles, was 94.0% (92.9\u201395.2%) in the OBI group compared with 58.4% (55.2\u201361.5%) in the Other group. Compliance with pegfilgrastim, defined as administration the day after chemotherapy, was 88.3% in the OBI group and 48.8% in the prefilled syringe group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients receiving pegfilgrastim OBI had a lower incidence of FN compared with those receiving alternatives. The OBI was associated with improved adherence to and compliance with clinically recommended G-CSF prophylaxis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07226-9","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T18:02:52Z","timestamp":1655920972000},"page":"7913-7922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices"],"prefix":"10.1007","volume":"30","author":[{"given":"Robert M.","family":"Rifkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma L.","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"MacLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanh","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad L.","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"7226_CR1","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916\u20131924","journal-title":"Cancer"},{"key":"7226_CR2","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"7226_CR3","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"7226_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00520-019-04795-0","volume":"28","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Bowers C, Garawin T, Kim C, Bensink ME, Chandler DB (2020) Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer 28:113\u2013122","journal-title":"Support Care Cancer"},{"key":"7226_CR5","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524\u20134531","journal-title":"J Clin Oncol"},{"key":"7226_CR6","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484","journal-title":"Ann Oncol"},{"key":"7226_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J (2013) A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 139:863\u2013872","journal-title":"Breast Cancer Res Treat"},{"key":"7226_CR8","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.1200\/jco.2006.24.18_suppl.8614","volume":"24","author":"P Biron","year":"2006","unstructured":"Biron P, Ray-Coquard I, Cesne AL, Dussart S, Goilliot C, Bachelot T, Thyss A, Gilles E, Chabaud S, Blay J (2006) ELYPSE 2: a prospective randomized trial comparing filgrastim (G-CSF) in primary and secondary prophylaxis in patients (pts) at high risk for febrile neutropenia (FN). J Clin Oncol 24:8614\u20138614","journal-title":"J Clin Oncol"},{"key":"7226_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/1471-2407-10-642","volume":"10","author":"L Gerlier","year":"2010","unstructured":"Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L (2010) The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin\u2019s lymphoma. BMC Cancer 10:642","journal-title":"BMC Cancer"},{"key":"7226_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4419-7073-2_8","volume":"157","author":"NM Kuderer","year":"2011","unstructured":"Kuderer NM (2011) Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. Cancer Treat Res 157:127\u2013143","journal-title":"Cancer Treat Res"},{"key":"7226_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jval.2011.05.042","volume":"14","author":"J Madan","year":"2011","unstructured":"Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S, Akehurst R (2011) Consistency between direct and indirect trial evidence: is direct evidence always more reliable? Value Health 14:953\u2013960","journal-title":"Value Health"},{"key":"7226_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337\u2013348","journal-title":"J Manag Care Pharm"},{"key":"7226_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"7226_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2009.05.019","volume":"31","author":"D Weycker","year":"2009","unstructured":"Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069\u20131081","journal-title":"Clin Ther"},{"key":"7226_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404","journal-title":"BMC Cancer"},{"key":"7226_CR16","unstructured":"Amgen Inc. (2020) Neulasta Prescribing Information.\u00a0https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Neulasta\/neulasta_pi_hcp_english.pdf"},{"key":"7226_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00280-016-2970-5","volume":"77","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Wang H, Reiner M, Page JH (2016) Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemother Pharmacol 77:703\u2013712","journal-title":"Cancer Chemother Pharmacol"},{"key":"7226_CR18","unstructured":"NCCN clinical practice guidelines in oncology hematopoietic growth factors version 2.2020. Available at: NCCN.org. Accessed January 7, 2021"},{"key":"7226_CR19","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","volume":"28","author":"PL Gawade","year":"2020","unstructured":"Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, Bradbury BD (2020) Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28:4413\u20134424","journal-title":"Support Care Cancer"},{"key":"7226_CR20","unstructured":"NCCN Short-term recommendations specific to issues with COVID-19. Available at: NCCN.org. Accessed January 7, 2021"},{"key":"7226_CR21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/ije\/dyv137","volume":"44","author":"DB Richardson","year":"2015","unstructured":"Richardson DB, Kinlaw AC, MacLehose RF, Cole SR (2015) Standardized binomial models for risk or prevalence ratios and differences. Int J Epidemiol 44:1660\u20131672","journal-title":"Int J Epidemiol"},{"key":"7226_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"7226_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"7226_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella I, Bermejo B, Insa A, P\u00e9rez-Fidalgo A, Magro A, Rosello S, Garc\u00eda-Garre E, Mart\u00edn P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479\u2013484","journal-title":"Breast Cancer Res Treat"},{"key":"7226_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","volume":"13","author":"N Denduluri","year":"2015","unstructured":"Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH (2015) Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw 13:1383\u20131393","journal-title":"J Natl Compr Canc Netw"},{"key":"7226_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7:99\u2013108","journal-title":"J Natl Compr Canc Netw"},{"key":"7226_CR27","first-page":"678","volume":"16","author":"SD Ramsey","year":"2010","unstructured":"Ramsey SD, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, Sullivan SD (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16:678\u2013686","journal-title":"Am J Manag Care"},{"key":"7226_CR28","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","volume":"25","author":"R Sosa","year":"2017","unstructured":"Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25:3123\u20133132","journal-title":"Support Care Cancer"},{"key":"7226_CR29","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1177\/1078155220956305","volume":"26","author":"AJ Gerberich","year":"2020","unstructured":"Gerberich AJ, Attilio MR, Svoboda A (2020) Revisiting same day administration of pegfilgrastim in the age of biosimilars: a review of literature. J Oncol Pharm Pract 26:1970\u20131976","journal-title":"J Oncol Pharm Pract"},{"key":"7226_CR30","first-page":"6","volume":"4","author":"RM Matera","year":"2021","unstructured":"Matera RM, Relias V, Wasif Saif M (2021) Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal malignancies. Cancer Med J 4:6\u201311","journal-title":"Cancer Med J"},{"key":"7226_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","volume":"34","author":"D Weycker","year":"2018","unstructured":"Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D (2018) Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged \u226565 years: a retrospective evaluation using Medicare claims. Curr Med Res Opin 34:1705\u20131711","journal-title":"Curr Med Res Opin"},{"key":"7226_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002532","author":"X Ma","year":"2021","unstructured":"Ma X, Kang J, Li Y, Zhang X (2021) Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002532","journal-title":"BMJ Support Palliat Care"},{"key":"7226_CR33","doi-asserted-by":"publisher","first-page":"e19542","DOI":"10.1200\/JCO.2021.39.15_suppl.e19542","volume":"39","author":"T Bartels","year":"2021","unstructured":"Bartels T, McBride A, AlRawashdh N, Moore L, Persky DO, Abraham I (2021) Same-day pegfilgrastim or pegfilgrastim-cbqv prophylaxis in miniCHOP chemotherapy based regimens for non-Hodgkin lymphoma. J Clin Oncol 39:e19542\u2013e19542","journal-title":"J Clin Oncol"},{"key":"7226_CR34","doi-asserted-by":"publisher","first-page":"e18687","DOI":"10.1200\/JCO.2021.39.15_suppl.e18687","volume":"39","author":"M Leiva","year":"2021","unstructured":"Leiva M, Pennisi A, Harnden KK, Rizzo PC, Mauro LA (2021) The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center. J Clin Oncol 39:e18687\u2013e18687","journal-title":"J Clin Oncol"},{"key":"7226_CR35","doi-asserted-by":"publisher","first-page":"e18591","DOI":"10.1200\/JCO.2021.39.15_suppl.e18591","volume":"39","author":"J Vraney","year":"2021","unstructured":"Vraney J, AlRawashdh N, Choi B, Abraham I, McBride A (2021) An institutional evaluation of the safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for lung cancer. J Clin Oncol 39:e18591\u2013e18591","journal-title":"J Clin Oncol"},{"key":"7226_CR36","doi-asserted-by":"crossref","unstructured":"Sandschafer D, Choi A, Lewis S, Upchurch T, De Oliveira Brandao C (2022) Assessment of device failures and medication errors with the pegfilgrastim on-body injector in the US and EU. Presented at ISPOR 2022: May 15\u201318","DOI":"10.1016\/j.jval.2022.04.1296"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07226-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:16:22Z","timestamp":1664183782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7226"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07226-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An internal review board approved the prespecified study protocol before initiating recruitment. The investigators obtained informed consent from each participant or each participant\u2019s legally acceptable representative.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Robert M. Rifkin reports participation in advisory boards for Amgen, BMS (Celgene), Coherus, Fresenius-Kabi, GSK, Janssen, and Pfizer. Jeffrey Crawford reports consulting fees from GlaxoSmithKline, G1 Therapeutics, Merck, Pfizer, Spectrum, and participation on a data safety monitoring board or advisory board for Beyond Spring, G1 Therapeutics, Merrimack, Mylan, and Roche. Reshma L. Mahtani reports consulting fees from Biotheranostics, Amgen, Agendia, Eisai, Immunomedics, Genentech, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, AstraZeneca, Daiichi, and participation on an advisory board for AstraZeneca, Amgen, Agendia, Biotheranostics, Eisai, Immunomedics, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, and Daiichi. David Dale reports consulting fees from Amgen, and contracted research support from Amgen. Sandra Lewis, Lucy DeCosta, and Tatiana Lawrence are employees and stockholders of Amgen. Prasad L. Gawade and Rajesh Belani were employees of Amgen; Rajesh Belani is an employee and a stockholder of Poseida Therapeutics. Mohit Narang, William W. MacLaughlin, and Chanh Huynh have no disclosures to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}